Abstract:Abstract Background A growing body of evidence has demonstrated a close association between nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) and its invasive presence systemically. Thus, several hospitals have implemented MRSA nares PCR screening for all patients initiating treatment active against MRSA for various infections to help de-escalate an anti-MRSA antibiotic in the event of a negative result. However, little is known about the effects of anti-MRSA systemic agents on MRSA nasal colonization, potentially affecting the use of MRSA PCR as an effective screening tool if not conducted immediately upon hospital admission. Methods Adult Upstate University Hospital patients ≥ 18 years of age with an initial positive MRSA nares PCR result were considered for inclusion, starting from September 2022. Eligible patients were individuals who had a positive MRSA nares PCR performed within 36 hours of their initial dose of a systemic anti-MRSA antibiotic. Positive MRSA nares cultures were also considered if PCRs were initially indeterminate. Anti-MRSA antibiotics included vancomycin, daptomycin, linezolid, ceftaroline, and clindamycin. Patients who were received these agents for a duration of 48-96 hours were consented for their participation. If consented, a follow-up MRSA nares swab and PCR were collected at a goal timepoint of 72 hours post initiation of anti-MRSA antibiotics (sample collection ranged from 48-96 hours post initiation). MRSA colonization was reassessed with a repeat nares PCR and reflex to culture for indeterminate results if applicable. Results As of April 21st, 2023, 61 follow-up MRSA nares samples were collected from eligible participants. Follow-up samples were collected an average of 66.51 hours after their first dose of anti-MRSA drugs (IQR = 11.47). Of these follow-up samples, 56/61 (91.80%) resulted as a positive MRSA nares PCR or culture result. Conclusion Our interim results demonstrated that MRSA colonization in the nares via PCR generally persists even after 48-96 hours of continuous systemic administration of anti-MRSA antibiotics. These findings suggest that MRSA nares swabs can still be used after anti-MRSA antibiotic administration, increasing its utility as a screening tool. Disclosures Wesley D. Kufel, Pharm.D., BCPS, BCIDP, AAHIVP, Merck & Co.: Grant/Research Support Elizabeth Asiago-Reddy, MD, Glaxo-Smith-Kline: Grant/Research Support|Pfizer: Grant/Research Support

Predictive values of methicillin-resistant Staphylococcus aureus nasal swabs for pneumonia in burn ICU patients

513 Predictive Values of MRSA Nasal Swabs for Pneumonia in Burn ICU Patients

Evaluating the Diagnostic Performance of Nasal Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction in Hospital-Acquired Pneumonia Within the Intensive Care Unit. A Retrospective Study

The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications

Antibiotic de-escalation in pneumonia with pharmacist education and ordering of methicillin-resistant Staphylococcus aureus nasal swabs

Assessing the Predictive Value of Methicillin-Resistant Staphylococcus aureus Nares Colonization Among Transplant Recipients and Patients With Neutropenia

MRSA nasal screening predictive values assessment in patients with osteomyelitis

Utility of methicillin-resistant Staphylococcus aureus nasal PCR testing in pediatric patients with suspected respiratory infections

Evaluation of Gram Stain-Guided Antibiotic Therapy for Methicillin-Resistant Staphylococcus aureus Pneumonia in Intensive Care Unit Patients

Evaluation of methicillin-resistant Staphylococcus aureus nasal swab screening at a large comprehensive cancer center

Risk Factors Affecting Nasal Colonization of Methicillin-Resistant Staphylococcus Aureus when Admitted in Intensive Care Unit

Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Real-Time PCR: A Predictive Tool for Contamination of the Hospital Environment

167. Duration of Methicillin-Resistant Staphylococcus aureus (MRSA) Nares PCR Positivity while Receiving Highly Active Anti-Staphylococcal Drugs

Molecular Quantification of Pseudomonas Aeruginosa from Respiratory Samples in Patients with Suspected Ventilator Associated Pneumonia

Rapid de-escalation of anti-MRSA therapy guided by S. aureus nares screening for patients with pneumonia: protocol of a randomized controlled trial (SNAP study)

Pediatric Clinical Outcomes of Nasal Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Utilization

Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Nares Test Positivity During Initial Days of Systemic Anti-Staphylococcal Antimicrobial Therapy

Alcohol-based Nasal Decolonization and Chlorhexidine Bathing to Reduce Methicillin-resistant Staphylococcus Aureus Hospital-acquired Infections in Critical Patients

Retrospective analysis of hospital-acquired pneumonia caused by Staphylococcus aureus in elderly patients

A Risk Factor Analysis for MRSA Ventilator-Associated Pneumonia to Guide Empiric Therapy in the Surgical Intensive Care Unit

Application of the prevention programme for methicillin resistant staphylococcus aureus ventilator associated pneumonia